Literature DB >> 8818831

Treatment of fungal infection in AIDS.

S Hood1, D W Denning.   

Abstract

Fungal infections affect virtually all patients with the Acquired Immunodeficiency Syndrome (AIDS). Superficial infection (seborrheic dermatitis, tinea capitis, tinea corporis and tinea cruris) is more common than in the general population and can be difficult to eradicate. Mucosal disease (oropharyngeal, oesophageal and vaginal candidosis) is very common and often recurs. In advanced AIDS, patients usually fail to respond to topical therapy and often to systemic therapy and isolates of Candida spp. from these patients are frequently resistant in vitro to fluconazole and other azoles. Systemic fungal infection is less common but life threatening. The commonest such infection is Pneumocystis carinii pneumonia (PCP) although prophylaxis is usually successful in preventing either the first episode or recurrent episodes. Histoplasmosis, coccidioidomycosis and Penicillium marneffei infections are common in endemic areas. Cryptococcal meningitis and invasive aspergillosis occur worldwide. The prophylaxis and treatment of all these except PCP are discussed and reviewed.

Entities:  

Mesh:

Year:  1996        PMID: 8818831     DOI: 10.1093/jac/37.suppl_b.71

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  3 in total

1.  In vitro activity of A-192411.29, a novel antifungal lipopeptide.

Authors:  A M Nilius; P M Raney; D M Hensey-Rudloff; W Wang; Q Li; R K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

2.  Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates.

Authors:  M E Kuipers; H G de Vries; M C Eikelboom; D K Meijer; P J Swart
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

3.  Pentamidine inhibition of group I intron splicing in Candida albicans correlates with growth inhibition.

Authors:  K E Miletti; M J Leibowitz
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.